| Balance Sheets | 2026-03-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 371,630 | |||
| Marketable securities | 166,854 | |||
| Prepaid expenses and other current assets | 5,456 | |||
| Total current assets | 543,940 | |||
| Total property and equipment | 21,492 | |||
| Less accumulated depreciation and amortization | 6,197 | |||
| Property and equipment, net | 15,295 | |||
| Operating lease right-of use assets | 12,816 | |||
| Restricted cash equivalents | 1,149 | |||
| Other assets | 3,601 | |||
| Total assets | 576,801 | |||
| Accounts payable | 1,227 | |||
| Accrued expenses and other current liabilities | 6,298 | |||
| Deferred revenue, current portion | 18,958 | |||
| Operating lease liabilities, current portion | 1,430 | |||
| Total current liabilities | 27,913 | |||
| Deferred revenue, net of current portion | 32,633 | |||
| Operating lease liabilities, net of current portion | 10,147 | |||
| Total liabilities | 70,693 | |||
| Redeemable convertible preferred stock-Series Seed Redeemable Convertible Preferred Stock | 0 | |||
| Redeemable convertible preferred stock-Series ARedeemable Convertible Preferred Stock | 0 | |||
| Redeemable convertible preferred stock-Series A-1Redeemable Convertible Preferred Stock | 0 | |||
| Redeemable convertible preferred stock-Series BRedeemable Convertible Preferred Stock | 0 | |||
| Redeemable convertible preferred stock-Partner Redeemable Convertible Preferred Stock | 0 | |||
| Common stock value-Common Stock | 5 | |||
| Common stock value-Common Class A | 0 | |||
| Additional paid-in capital | 681,233 | |||
| Accumulated other comprehensive (loss) income | -241 | |||
| Accumulated deficit | -174,889 | |||
| Total stockholders' equity (deficit) | 506,108 | |||
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 576,801 | |||
Aktis Oncology, Inc. (AKTS)
Aktis Oncology, Inc. (AKTS)